Brain Tumours Application

Hanalytics (BioMind)
Assists in the detection, segmentation, differential diagnosis and localization of 22 types of intracranial tumors on MRI scans: chordoma, lymphoma, craniopharyngioma, choroid plexus, papilloma, meningioma, medulloblastoma, epidermoid cyst, pituitary tumor, paraganglioma, germ cell tumor, acoustic neuroma, angioreticuloma, DNET, hemangiopericytoma, pleomorphic yellow, astrocytoma, nodular cell tumor, brain metastases, astrocytoma, oligodendroglioma, glioblastoma, pilocytic astrocytoma, ependymoma, subependymal giant, cell astrocytoma.
biomind-brain-tumor.jpg
Information source: Vendor
Last updated: December 3, 2020

General Information

General
Product name Brain Tumours Application
Company Hanalytics (BioMind)
Subspeciality Neuro
Modality MR
Disease targeted Brain tumours, brain cancer
Key-features Brain tumor detection, segmentation and brain region localization, 3D reconstruction, structured report generation
Suggested use During: perception aid (prompting all abnormalities/results/heatmaps), interactive decision support (shows abnormalities/results only on demand), report suggestion
After: diagnosis verification

Technical Specifications

Data characteristics
Population Patients suspected of brain tumours, not valid for children under 8-year-old
Input T1, T2, T2 Contrast, Axial
Input format DICOM
Output segmentation overlay, brain region overlay, structured report
Output format DICOM, Nifty
Technology
Integration Integration in standard reading environment (PACS), Integration RIS (Radiological Information System), Integration CIS (Clinical Information System), Integration via AI marketplace or distribution platform, Stand-alone third party application
Deployment Locally on dedicated hardware, Cloud-based
Trigger for analysis Automatically, right after the image acquisition, On demand, triggered by a user through e.g. a button click, image upload, etc.
Processing time 3 - 10 seconds

Regulatory

Certification
CE
Certified, Class IIa , MDD
FDA No or not yet
Intended Use Statements
Intended use (according to CE)

Market

Market presence
On market since 12-2017
Distribution channels
Countries present (clinical, non-research use) 27
Paying clinical customers (institutes) +140
Research/test users (institutes) 15
Pricing
Pricing model One-off payment
Based on Number of installations

Evidence

Evidence
Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers